Literature DB >> 20821390

The developability classification system: application of biopharmaceutics concepts to formulation development.

James M Butler1, Jennifer B Dressman.   

Abstract

A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the in vivo performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to in vivo performance than the widely used BCS.
© 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Mesh:

Substances:

Year:  2010        PMID: 20821390     DOI: 10.1002/jps.22217

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

Review 1.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry.

Authors:  Michael M Hann; György M Keserü
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

2.  Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling.

Authors:  Hai Pham-The; Gerardo Casañola-Martin; Teresa Garrigues; Marival Bermejo; Isabel González-Álvarez; Nam Nguyen-Hai; Miguel Ángel Cabrera-Pérez; Huong Le-Thi-Thu
Journal:  Mol Divers       Date:  2015-12-07       Impact factor: 2.943

3.  Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.

Authors:  Filippos Kesisoglou
Journal:  AAPS PharmSciTech       Date:  2014-02       Impact factor: 3.246

4.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

5.  Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.

Authors:  Duncan Richards; Mark Bamford; Lia Liefaard; Nazneen Haque; Gareth Lewis; Jim Storey; Disala Fernando; Subramanya Kumar; Douglas Thompson; Duncan S Holmes
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

6.  "Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.

Authors:  Bart Hens; Maura Corsetti; Marival Bermejo; Raimar Löbenberg; Pablo M González; Amitava Mitra; Divyakant Desai; Dakshina Murthy Chilukuri; Alexis Aceituno
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

7.  Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.

Authors:  Arzu Selen; Anette Müllertz; Filippos Kesisoglou; Rodney J Y Ho; Jack A Cook; Paul A Dickinson; Talia Flanagan
Journal:  AAPS J       Date:  2020-07-27       Impact factor: 4.009

8.  Insights and Lessons from a Scientific Conference on Non-Invasive Delivery of Macromolecules.

Authors:  Ronak Savla; Randall J Mrsny; Kinam Park; Isabelle Aubert; Cornell Stamoran
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

9.  The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration.

Authors:  Alexandros Kourentas; Maria Vertzoni; Vicky Barmpatsalou; Patrick Augustijns; Stefania Beato; James Butler; Rene Holm; Neils Ouwerkerk; Joerg Rosenberg; Tomokazu Tajiri; Christer Tannergren; Mira Symillides; Christos Reppas
Journal:  AAPS J       Date:  2018-05-24       Impact factor: 4.009

10.  Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.